$3.57
-0.33-8.46%
Last update: Nov 10, 4:00 PM
Kyntra Bio Inc
KYNBNASDAQ
Kyntra Bio fell 60.8% from $9.94 to $3.90, behind the S&P 500's +9.8%. Its worst day was Feb 24 (−9.6%), and its low came Nov 5 at $3.66.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kyntra Bio closed at its highest level of the year, 1.0% above where the year started.
+19.8%, the year's best day · S&P 500 −0.2%
Kyntra Bio shares rose 9.6%, while the S&P 500 rose 1.9%.
+9.6% · S&P 500 +1.9%
Story events cover the past 12 months · Times ET
Kyntra Bio shares fell 9.6%, while the S&P 500 rose 0.7%.
−9.6%, the year's worst day · S&P 500 +0.7%
EPS of $-3.61 beat the $-3.89 estimate on $1.3M revenue (est. $1.6M).
+5.3% · S&P 500 +0.3%
EPS of $-3.74 was reported on $3.7M revenue.
+6.3% · S&P 500 −0.2%
EPS of $-4.68 missed the $-3.18 estimate on $-1.5M revenue (est. $2.0M).
+0.1% · S&P 500 −0.2%
Kyntra Bio shares fell 9.5%, while the S&P 500 fell 1.1%.
−9.5% · S&P 500 −1.1%
Where it ended: a close of $3.90 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-3.40, revenue est. $1.8M).
Nothing in the past 12 months.
All KYNB dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KYNB and SPY from Benzinga historical bars. Not investment advice.
